Secukinumab in HS

Published in Dermatology

Journal Scan / Research · February 27, 2020

Secukinumab in the Treatment of Moderate to Severe Hidradenitis Suppurativa

Journal of the American Academy of Dermatology

TAKE-HOME MESSAGE

• This open-label trial assessed the impact of secukinumab treatment on moderate to severe hidradenitis suppurativa. After a loading dose of 5 weekly injections at 300 mg, patients received 300 mg either every 4 weeks or every 2 weeks. At week 24, 70% patients had achieved clinical response (at least a 50% reduction in lesion count and no increase in draining fistula or abscess). Lesion count reductions at ≥50%, ≥75%, and 100% were 65%, 20%, 5% and 75%, 35%, 15% at weeks 12 and 24, respectively. Mean time to achieve clinical response was 7 weeks. No serious adverse events were observed.

• Despite being a small open-label study, these early data provide evidence that targeting IL-17 may be a viable treatment option in this therapeutically challenging condition.

– InYoung Kim, MD, PhD

Abstract

Hidradenitis suppurativa (HS) is an inflammatory skin disease that is challenging to treat. HS patients have imbalances in the T-helper-17-cell (Th17) axis that are similar to those in psoriasis patients.They have high serum levels of the proinflammatory cytokine, interleukin-17A (IL-17A), which leads to neutrophil recruitment and provides positive feedback to maintain the population of proinflammatory Th17 cells.1,2 These imbalances improve with anti-tumor-necrosis-factor-α (anti-TNFα) biologics.3 It is hypothesized that by reducing circulating IL-17A, anti-interleukin-17A biologics such as secukinumab may also treat HS.  Secukinumab (Cosentyx™, Novartis) is a human monoclonal IgG1k antibody that selectively binds to IL-17A. Our study aimed to look at the effects of secukinumab on lesions in patients with moderate-to-severe HS.

Journal of the American Academy of Dermatology

Secukinumab in the Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Results of an Open-Label Trial

J Am Acad Dermatol 2020 Feb 07;[EPub Ahead of Print], RG Casseres, L Prussick, P Zancanaro, B Rothstein, D Joshipura, A Saraiya, Y Turkowski, SC Au, A Alomran, R Abdat, M Abudu, C Kachuk, N Dumont, AB Gottlieb, D Rosmarin 

Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.